Direct answer:After receiving reports of serious adverse events related to the use of their products in the United States, the cosmetics Responsible Person must report to the FDA within 15 working days, with a copy of the label on the retail packaging or accompanying it. Medical or other new information received within one year of the initial report must be submitted within 15 working days of receipt. The enterprise should not wait until the final causal investigation has been completed before time management is initiated.

Who is responsible for reporting?

Responsible Person is the manufacturer, packaging or distributor whose name appears on the cosmetic label. The actual production plant, brand side and U.S. agent may not be the same subject; The contract may agree on the transmission of information and assistance, subject to the identification of the legal person responsible. The exemption for registered or listed small businesses does not automatically exempt them from reporting obligations for serious adverse incidents.

What is the preliminary distinction between complaints and serious incidents?

Not every miscalculation, damaged packaging or mild discomfort is considered to be a serious adverse event. The severity criteria for MoCRA include circumstances such as death, danger to life, hospitalization, continued or significant disability or incapacity, congenital abnormality, infection, significant disfigurement, and the need for medical or surgical intervention to prevent a relevant serious result based on a reasonable medical judgement. Businesses should be judged by FDA definitions and facts and cannot simply use “refunds” or “consumers have failed to prove cause and effect” to close events.

What do we do when we get the feedback?

  1. (a) Registration of the date of receipt, the source of information and the identity of the product, timely upgrading to the designated person responsible and assessment of seriousness; Do not delay the necessary medical disposal.
  2. (c) Collating the history of events, the time spent, the symptoms and the medical information available, and maintaining the original consumer feedback and follow-up records.
  3. Preparation of available identifying information for product names, batches, etc., and copies of retail labels, in accordance with the current FDA form and submission of narrative reports; Avoid disclosure of personal privacy in public material.
  4. Maintenance of the submission of evidence and tracking of additional information, and management of a new 15 working day period when relevant new information is received within one year of the initial report.

The submission of the report does not amount to an acknowledgement of the harm caused by the product. Non-serious adverse events may be reported on a voluntary basis, but enterprises should still record and deal with them in accordance with applicable requirements. Specific fields and channels of submission should be based on the current narrative of the FDA.

Retention of records and draft boundary

MoCRA has a retention obligation for the recording of adverse events, generally for a period of six years, which is applicable for a period of three years if the conditions for the corresponding small business are met. The original complaint and the follow-up information cannot be discarded simply by preserving the submission form. The FDA 2026 document on access to cosmetics records is currently a draft and cannot be implemented as a final guide; Existing statutory reporting and retention obligations should be understood separately from the draft recommendations.

Official sources are checked with recent information.

What's next?

The identification of label duty-bearers, consumer feedback reception channels and intra-enterprise upgrading processes and the designation of duty-bearers to report and supplement information. CombinableMoCRA Guide to Registration and ListingChecking other obligations or adoptingCosmetics compliance servicesCombination of liability arrangements.

Preparation for first release and verification of official information: 2026-11-05. Author: Mr. Otsun; Audit: Mr. Toto.

View cosmetics FDA compliance serviceView pricing and order online ↗

Continue reading and preparation

Further consolidation of project information is availableMoCRA Compliance Advisory and Ongoing Maintenance; The scope, processing cycles and costs are shown on the corresponding service page.